MedPath

A comparative study of two drugs

Phase 4
Conditions
Health Condition 1: O- Medical and Surgical
Registration Number
CTRI/2024/05/067274
Lead Sponsor
Dr Ambati Mounika
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Patients of ASA grade 1 and 2 who are undergoing

elective surgery under general anesthesia

2 Patients who consent to participate in the study

3 Patients having informant available

Exclusion Criteria

1Difficult airway

2Hypertension

3Diabetes mellitus

4ischemic heart disease

5renal diseases

6Cerebrovascular Disease

•Patients on beta blockers

alpha blockers

•Bronchial asthma

•Allergy to study drug

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Dexmeditomidine 1µ/Kg given slowly over 10 minutes intravenously 5 minutes prior to induction, attenuates the cardiovascular responses to laryngoscopy and intubation in a better manner than Labetalol 0.25mg/Kg.Timepoint: post intubation vitals are measured every 3minutes for first 15minutes
Secondary Outcome Measures
NameTimeMethod
To observe the effect of Dexmedetomidine in attenuating the hemodynamic stress response during Laryngoscopy and intubation <br/ ><br>2)To observe the effect of labetalol in attenuating hemodynamic stress response during Laryngoscopy and Intubation <br/ ><br>3)To compare between Dexmedetomidine and Labetalol in the specified dosage. <br/ ><br>Timepoint: post intubation vitals are measured every 3minutes for first 15minutes
© Copyright 2025. All Rights Reserved by MedPath